Results 11 to 20 of about 82,921 (179)

PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis. [PDF]

Cochrane Database Syst Rev, 2023
Asparaginase has played a crucial role in the improvement of survival in children with acute lymphoblastic leukaemia (ALL), which is the commonest cancer among children. Survival rates have steadily increased over decades since the introduction of asparaginase to ALL therapy, and overall survival rates reach 90% with the best contemporary protocols ...
Lynggaard LS, Rank CU, Als-Nielsen B, Hoejfeldt SG, Heyman M, Schmiegelow K, Albertsen BK.   +6 more
europepmc   +6 more sources

Affordable and safe health care for all children: Lessons learned from the use of peg-asparaginase in a developing country [PDF]

Indian Journal of Medical and Paediatric Oncology, 2017
Peg-asparaginase has widely replaced the use of conventional asparaginase in treatment of children with acute lymphoblastic leukaemia in developed countries.
Dhaarani Jayaraman, Ramya Uppuluri, Venkateswaran Vellaichamy Swaminathan, Meena Sivasankaran, Shivani Patel, Revathi Raj   +5 more
doaj   +3 more sources

Cetoacidose diabética e pancreatite secundárias à peg-asparaginase. [PDF]

Medicina (Ribeirão Preto), 2021
Objetivos: Apresentar um caso raro de cetoacidose diabética (CAD) e pancreatite secundários ao uso de PEG-asparaginase em paciente pediátrico em tratamento para leucemia linfoblástica aguda (LLA) e alertar quanto aos sinais que remetem a esses diagnósticos.
Frederico Ribeiro Pires, Camila Abreu de Souza, Murilo Brito Luiz, Selma Harue Kawahara, Luiz Claudio Gonçalves de Castro   +4 more
openaire   +4 more sources

RETRACTED: Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study

Frontiers in Oncology, 2020
BackgroundAsparaginase-associated pancreatitis (AAP) is one of the most common complications occurring in patients with asparaginase-treated acute lymphoblastic leukemia (ALL).
Yun-yu Zhang, Qiu-shi Yang, Xia Qing, Bi-ru Li, Juan Qian, Ying Wang, Bo-tao Ning   +6 more
doaj   +2 more sources

Acute Pancreatitis Caused by Pegylated (PEG)-Asparaginase Associated With Severe Hypertriglyceridemia. [PDF]

Cureus
Pegylated (PEG)-asparaginase is used during the induction and intensification phases of treatment for B-cell acute lymphoblastic leukemia (B-ALL). It works by depleting the external sources of asparagine, causing the death of lymphoblasts. It has several adverse effects, including pancreatitis and hypertriglyceridemia; however, the simultaneous ...
Rai S, Sharma P, Nepal A, Poudel S, Guerra Y.   +4 more
europepmc   +3 more sources

PEG‐asparaginase treatment for acute lymphoblastic leukaemia in children: a network meta‐analysis [PDF]

Cochrane Database Syst Rev, 2021
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effect of the number of PEG-asparaginase doses on survival and relapse in children and adolescents with acute lymphoblastic leukaemia (ALL). Secondary objectives To assess the association between the number of doses of PEG-asparaginase and
Lynggaard L, Rank C, Als-Nielsen B, Hoejfeldt S, Heyman M, Schmiegelow K, Albertsen B.   +6 more
europepmc   +2 more sources

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol [PDF]

HemaSphere, 2023
The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as
Carmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, Valentino Conter, Martin Zimmermann, Daniela Silvestri, Andishe Attarbaschi, Felix Niggli, Draga Barbaric, Jan Stary, Sarah Elitzur, Gunnar Cario, Luciana Vinti, Joachim Boos, Massimo Zucchetti, Claudia Lanvers-Kaminsky, Arend von Stackelberg, Andrea Biondi, Martin Schrappe   +18 more
doaj   +2 more sources

IS THERE AN ASSOCIATION BETWEEN PULMONARY EMBOLISM AND THE USE OF PEG-ASPARAGINASE IN CHILDREN WITH LEUKEMIA?

Hematology, Transfusion and Cell Therapy, 2023
We present two leukemic children who developed pulmonary thromboembolism (PTE) after using PEG-asparaginase.The first child, an eight-year-old boy, was diagnosed with T-acute lymphoblastic leukemia (ALL). The second child, a 6-year-old boy, was diagnosed
Emine Yılmaz Orulluoğlu, Zühre Kaya, Merve Yazol, Büşra Topuz Turkcan, Serap Kirkiz Kayalı, Ülker Koçak   +5 more
doaj   +2 more sources

Blinatumomab restores asparaginase activity in pediatric B-cell acute lymphoblastic leukemia patients with PEG-Asparaginase hypersensitivity [PDF]

Haematologica
Not available.
Xue Tang, Lingying Zhao, Wujiao Li, Shilin Liu, Xuejuan Li, Lixiang Zhu, Duocai Wang, Shiyang Chen, Zhaonan Liu, Sixi Liu, Feiqiu Wen, Oussama Abla, Ying Wang, Huirong Mai, Xiaoying Fu   +14 more
doaj   +2 more sources

Peg-Grafted Liposomes for L-Asparaginase Encapsulation [PDF]

Pharmaceutics, 2022
L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired ...
Marina de Souza Guimarães, Jorge Javier Muso Cachumba, Cecilia Zorzi Bueno, Karin Mariana Torres-Obreque, Grace Verónica Ruiz Lara, Gisele Monteiro, Leandro Ramos Souza Barbosa, Adalberto Pessoa, Carlota de Oliveira Rangel-Yagui   +8 more
doaj   +2 more sources